GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » Notes Receivable

Tevogen Bio Holdings (FRA:G28) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Notes Receivable?

Tevogen Bio Holdings's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Tevogen Bio Holdings Notes Receivable Historical Data

The historical data trend for Tevogen Bio Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Notes Receivable Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tevogen Bio Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Tevogen Bio Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tevogen Bio Holdings Business Description

Traded in Other Exchanges
Address
15 Independence Boulevard, Warren, NJ, USA, 07059
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines